Treatment Algorithms in Metastatic Renal Cell Carcinoma, Including the Potential Role of the Novel Oral Mammalian Target of Rapamycin Inhibitor Everolimus

European Urology, Supplements

Volumn 8, Issue 10, 2009, Pages 809-814

  Patard, Jean Jacques ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

Everolimus; First line; mTOR; Renal cell carcinoma; Second line; Treatment algorithms; VEGF targeted therapy

Indexed keywords

BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR;

ALGORITHM; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RISK; CANCER SURGERY; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 70349309315     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2009.08.004     Document Type: Review

References (38)

1. NCCN clinical practice guidelines in oncology: kidney cancer. National Comprehensive Cancer Network Web site. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed June 2009.
2. International Agency for Research on Cancer. GLOBOCAN database 2002. CANCERMondial Web site. http://www-dep.iarc.fr. Accessed June 2009.
3. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
4. Costa L.J., and Drabkin H.A. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12 (2007) 1404-1415
5. National Cancer Institute. Surveillance, Epidemiology and End Results (SEER) cancer statistics review: kidney and renal pelvis cancer; 5-yr relative survival rates, 1999-2005. http://seer.cancer.gov/csr/1975_2006/browse_csr.php?section=11&page=sect_11_table07.html. Accessed June 2009.
6. Kim W.Y., and Kaelin W.G. Role of VHL gene mutation in human cancer. J Clin Oncol 22 (2004) 4991-5004
7. Patard J.J., Pouessel D., and Culine S. New therapies in renal cell carcinoma. Curr Opin Support Palliat Care 1 (2007) 174-179
8. Ravaud A., Wallerand H., Culine S., et al. Update on the medical treatment of metastatic renal cell carcinoma. Eur Urol 54 (2008) 315-325
9. Maluf F.C., Fernandes G.S., Kann A.G., Aguilar-Ponce J.L., de la Garza J., and Buzaid A.C. Exploring the role of novel agents in the treatment of renal cell carcinoma. Cancer Treat Rev 34 (2008) 750-760
10. Motzer R.J., Mazumdar M., Bacik J., Berg W., Amsterdam A., and Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17 (1999) 2530-2540
11. Leibovich B.C., Cheville J.C., Lohse C.M., et al. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol 174 (2005) 1759-1763
12. Coppin C, Le L, Porzsolt F, Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2008:CD006017.
13. Safety and efficacy of bevacizumab plus RAD001 versus interferon alfa-2a and bevacizumab in adult patients with kidney cancer (L2201) [identifier NCT00719264]. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00719264. Accessed June 2009.
14. Efficacy and safety comparison of RAD001 versus sunitinib in the first-line and second-line treatment of patients with metastatic renal cell carcinoma (RECORD3) [identifier NCT00903175]. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00903175. Accessed June 2009.
15. Motzer R.J., Escudier B., Oudard S., et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372 (2008) 449-456
16. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
17. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 26 (2008) abstract 5024
18. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27 (2009) 3984-3990
19. Bellmunt J., Calvo E., Castellano D., et al. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. Cancer Chemother Pharmacol 63 Suppl 1 (2009) S1-13
20. Nathan P., Wagstaff J., Porfiri E., Powles T., and Eisen T. UK guidelines for the systemic treatment of renal cell carcinoma. Br J Hosp Med (Lond) 70 (2009) 284-286
21. Mejean A., and Lebret T. Prise en charge of metastatic renal carcinoma. Prog Urol 18 Suppl 7 (2008) S298-308
22. Hotte S, Waldron T, Bjarnason G, et al. The use of inhibitors of angiogenesis in patients with inoperable locally advanced or metastatic renal cell cancer: guideline recommendations. Cancer Care Ontario Web site. http://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=43559. Accessed June 2009.
23. de Reijke T.M., Bellmunt J., van Poppel H., Marreaud S., and Aapro M. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer 45 (2009) 765-773
24. Escudier B., and Kataja V. Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 Suppl 4 (2009) iv81-2
25. Ljungberg B, Hanbury DC, Kuczyk MA, et al. Guidelines on renal cell carcinoma. European Association of Urology Web site. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf. Accessed June 2009.
26. Escudier B., Pluzanska A., Koralewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
27. Escudier B.J., Bellmunt J., Negrier S., et al. Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-a2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin Oncol 27 (2009) abstract 5020
28. Rini B.I., Halabi S., Rosenberg J., et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206. J Clin Oncol 27 (2009) abstract LBA5019
29. Rini B.I., Halabi S., Rosenberg J.E., et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26 (2008) 5422-5428
30. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281
31. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
32. Bukowski R.M., Eisen T., Szczylik C., et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. J Clin Oncol 25 (2007) abstract 5023
33. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
34. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
35. Escudier B., Ravaud A., Oudard S., et al. Phase-3 randomized trial of everolimus (RAD001) vs placebo in metastatic renal cell carcinoma [abstract 72]. Ann Oncol 19 (2008) viii45
36. Motzer R, Kay A, Figlin R, et al. Updated data from a phase III randomized trial of everolimus (RAD001) versus PBO in metastatic renal cell carcinoma (mRCC). ASCO 2009 Genitourinary Cancers Symposium [abstract 278]. American Society of Clinical Oncology Web site. http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=64&sessionID=11. Accessed June 2009.
37. George D.J., Michaelson M.D., Rosenberg J.E., et al. Phase II trial of sunitinib in bevacizumab-refractory metastatic renal cell carcinoma (mRCC): updated results and analysis of circulating biomarkers. J Clin Oncol 25 (2007) abstract 5035
38. Oxford Centre for Evidence Based Medicine. Centre for Evidence Based Medicine Web site. http://www.cebm.net. Accessed June 2009.